CDK1 and diffuse large B-cell lymphoma: Besides, the cell cycle kinase, CDK1, was upregulated in high-risk group, and BARASERTIB and DINACICLIB might be the potential drugs for treating DLBCL classified as high-risk (Figure 6D).